Carnicetin capsules 295mg, No. 60

• Initial dementia of the Alzheimer's type (Alzheimer's disease) and cerebrovascular dementia;

• Peripheral neuropathy of various etiologies;

• Primary and secondary involutional syndromes against the background of vascular encephalopathy;

• Decreased mental performance, to improve concentration and memory.

Carnicetin is taken orally. A single dose for adults is usually 1-4 capsules, a daily dose of 6-12 capsules. The course of treatment is 1-4 months.

active substance - acetylcarnitine hydrochloride (carnicetine) 0.295 g (corresponds to 0.25 g of acetylcarnitine),

excipients: microcrystalline cellulose, colloidal silicon dioxide (Aerosil A-300), magnesium stearate to obtain the mass of the capsule contents of 0.34 g;

hard gelatin capsules: capsule composition: gelatin, glycerol (glycerin), nipagin (methyl parahydroxybenzoate), nipazole (propyl parahydroxybenzoate), sodium lauryl sulfate, purified water, titanium dioxide.

• Individual hypersensitivity to the drug;

• Age up to 18 years (efficacy and safety have not been established).

Trade name of the drug: CarnicetinЃ

International Non-Proprietary Name (Generic Name): Acetylcarnitine

Dosage form:

capsules

Composition:

active substance - acetylcarnitine hydrochloride (carnicetine) 0.295 g (corresponds to 0.25 g of acetylcarnitine),

excipients: microcrystalline cellulose, colloidal silicon dioxide (Aerosil A-300), magnesium stearate to obtain the mass of the capsule contents of 0.34 g;

hard gelatin capsules: capsule composition: gelatin, glycerol (glycerin), nipagin (methyl parahydroxybenzoate), nipazole (propyl parahydroxybenzoate), sodium lauryl sulfate, purified water, titanium dioxide.

Description: the contents of the capsules are powder from white to white with a yellowish sheen, with a faint odor of acetic acid. White capsules No. 0.

Pharmacotherapeutic group:

metabolic agent.

ATX code: [N06BX12]

Pharmacological properties

Pharmacodynamics.Acetyl-L-carnitine (ALA), a natural biologically active substance present in the body under physiological conditions in various organs and tissues, including the central nervous system, is involved in the metabolism of fatty acids and carbohydrates. The pharmacological and biological effects of ALA are largely due to the metabolic effects of L-carnitine and the acetyl group that make up its composition. Acetyl-L-carnitine (ALA), the biologically active form of L-carnitine, a key substance in the body's fat catabolism and energy production. ALA is synthesized in the brain tissue, liver and kidneys from L-carnitine with the participation of the enzyme carnitine acetyltransferase. Since ALA supplies activated acetate directly to the mitochondrial matrix for the formation of acetyl-CoA, which is involved in the tricarboxylic acid cycle, without additional energy consumption,it is a readily available substrate for triggering energy-dependent metabolic processes in mitochondria. Due to the full energy supply of the body with less oxygen consumption by the tissues, ALA protects the brain tissues from ischemia.

Due to its structural similarity to acetylcholine, ALA has a cholinomimetic effect as well as neuroprotective properties. It increases the cellular concentration of aspartic and glutamic acid, as well as taurine; with prolonged use, it increases the density of N-methyl-D-aspartate receptors in the hippocampus, cortex and striatum and prevents a decrease in their density under aging conditions. ALA enhances the effects of serotonin and also protects brain cells from the neurotoxic effects of ammonia and glutamate.

The results of experimental studies have shown that ALA has antiamnestic activity, the ability to improve learning processes, indicators of non-associative memory, to have a positive effect on mnestic functions in an experimental model of Alzheimer's disease, without causing side effects of a sedative and muscle relaxant nature.

ALA increases energy production by being a readily available substrate for triggering energy-dependent metabolic processes in mitochondria. Stimulates the synthesis of proteins and phospholipids for building membranes, improves regeneration processes. In pathology, it has a neuroprotective effect, especially in relation to neurons and their organelles (mitochondria), as well as a neurotrophic effect by modulating the activity of nerve growth factor (NGF). It has an antioxidant and membrane stabilizing effect. ALA can accelerate the regeneration of nerve cells in traumatic and endocrine damage to peripheral nerves in experimental models of polyneuropathy in diabetes.

ALA has a noticeable effect on slowing down the aging process by increasing the transport of fatty acids into mitochondria and maintaining their work at the level of a young organism. ALA can accelerate the regeneration of nerve cells in traumatic and endocrine damage to peripheral nerves in experimental models of diabetes.

Pharmacokinetics. In animal studies, when taken orally (500 mg / kg), the maximum concentration of the drug in the blood occurs after 4 hours and is 40 µM / L within 8 hours. Absorption of ALA from the gastrointestinal tract occurs due to active transport or by simple diffusion through the mucous membrane (provided its concentration is high). In most tissues, including the cerebral, ALA comes from the bloodstream (with the exception of the liver and small intestine) unchanged. ALA enters the cell through a direct energy-dependent process against the concentration gradient. It is excreted from the body by the kidneys.

Indications for use

• Initial dementia of the Alzheimer's type (Alzheimer's disease) and cerebrovascular dementia;

• Peripheral neuropathy of various etiologies;

• Primary and secondary involutional syndromes against the background of vascular encephalopathy;

• Decreased mental performance, to improve concentration and memory.

Contraindications

• Individual hypersensitivity to the drug;

• Age up to 18 years (efficacy and safety have not been established).

Application during pregnancy and lactation

Special studies on the possibility of use during pregnancy and during breastfeeding have not been carried out; used only if the intended benefit to the mother outweighs the risk to the fetus. During treatment, breastfeeding should be discontinued.

Method of administration and dosage

Carnicetin is taken orally. A single dose for adults is usually 1-4 capsules, a daily dose of 6-12 capsules. The course of treatment is 1-4 months.

Side effect

Allergic reactions are possible; nausea, heartburn.

Overdose

Overdose cases have not been registered.

Interaction with other medicinal products

No drug interactions have been reported.

Release form

Capsules of 295 mg. 60 capsules in polymer jars with lids.
10 capsules in a blister strip made of polyvinyl chloride film and aluminum foil.
A jar or 6 blister strip packs, together with instructions for use, are placed in a cardboard box.

Storage conditions

In a dry, dark place at a temperature not exceeding 25 ? C.
Keep out of the reach of children.

Shelf life

2 years. Do not use after the expiration date.

Dispensing from pharmacies

On prescription.